Melanotan II

Quickstart Highlights

Melanotan II is a synthetic analog of α-melanocyte-stimulating hormone studied for its ability to increase skin pigmentation and noted for inducing erectile activity as a side effect. An early three-participant human study observed pigmentation changes. It did not establish a generally safe or effective tanning regimen. Primary pilot study.

• Reconstitute: 2.4 mL BAC water per labelled 10 mg vial. Calculations assume a final volume of 2.4 mL (4.16667 mg/mL nominal).
• Scale conversion: 1 U-100 unit = 0.01 mL; at this concentration, that corresponds to 41.66667 mcg.
• Storage: Lyophilized: freeze at −20 °C (−4 °F) or below; after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 1–2 weeks.

Protocol Overview

Measurement-reference overview.

• Goal: Increase skin pigmentation (tanning) through melanocortin receptor activation.
• Reconstitution: 2.4 mL BAC per labelled 10 mg vial; nominal 4.16667 mg/mL under the stated final-volume assumption.
• Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); use within 1–2 weeks.

Measurement scope

These are concentration-to-volume calculation examples. The amounts shown do not establish a recommended dose, frequency, escalation schedule or treatment duration. The evidence reviewed for this page does not validate the previous schedule for this product and use.

Storage Instructions

Proper storage preserves peptide stability and potency.

• Lyophilized: Store at −20 °C (−4 °F) or below in dry, dark conditions; keep desiccated to minimize moisture exposure.
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 1–2 weeks with bacteriostatic water preservative.
• Avoid freeze–thaw: Do not refreeze reconstituted solution; prepare aliquots if longer storage needed.
• Allow vials to reach room temperature before opening to reduce condensation.

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes for each injection; dispose in a sharps container immediately.
• Rotate injection sites systematically (abdomen, thighs, upper arms) to reduce local irritation and scarring.
• Clean vial stopper and injection site with alcohol swabs before each use; allow to air dry.
• Inject slowly and steadily; wait a few seconds before withdrawing the needle.
• Document the measured amount, injection site, and any side effects to maintain consistency and track tolerance.
• Safety warning: No safe daily limit is established by the evidence cited here. Serious adverse-event reports should not be interpreted as showing that lower amounts are safe.

How This Works

Melanotan II is a synthetic cyclic heptapeptide analog of α-melanocyte-stimulating hormone that binds to melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes stimulates melanin production and distribution, resulting in increased skin pigmentation even without UV exposure. The small early human study observed pigmentation changes, but it did not establish a generally safe or effective tanning regimen or validate the daily schedule on this page. Primary pilot study.

Potential Benefits & Side Effects

Observations from clinical trials and case reports.

Potential Benefits

• Increases skin pigmentation (tanning) without UV exposure requirement.
• May induce spontaneous erections in men as a noted side effect (MC4R activation).

Common Side Effects

• Nausea (dose-dependent; most common at higher doses).
• Facial flushing and increased skin warmth.
• Reduced appetite and mild fatigue.
• Spontaneous erections or increased libido in men.
• Injection site reactions (redness, mild stinging).

Serious Risks & Warnings

• Not FDA-approved: Melanotan II is not an approved medication; use carries regulatory and safety risks.
• Serious adverse-event reports: Severe systemic reactions and rhabdomyolysis have been reported after use. Case reports do not define a safe dose threshold.
• Mole changes and melanoma reports: FDA identifies published melanoma case reports among the reported safety concerns. Such reports do not establish causation or quantify risk, but the concern should not be described as purely theoretical. FDA safety assessment.
• Cardiovascular effects: Transient increases in heart rate and blood pressure possible at higher doses.

Lifestyle Factors

Complementary strategies for safe and effective outcomes.

• UV exposure: Do not treat induced pigmentation as protection from UV damage or as a reason to seek tanning exposure. Health Canada tanning guidance.
• Hydration: Maintain adequate fluid intake, especially if experiencing nausea or appetite suppression.
• Monitoring: Inspect moles and skin regularly for changes; seek dermatological evaluation if new or changing lesions appear.
• Safety context: No generally safe daily ceiling has been established. Lower amounts should not be assumed safe because serious reactions have been reported at larger amounts.

Injection Technique

Subcutaneous injection guidance from clinical best-practice resources.

• Clean the vial stopper and injection site with alcohol swabs; allow both to air dry completely.
• Use a 1 mL insulin syringe (29–31 gauge, ½ inch needle) for subcutaneous administration.
• Pinch a fold of skin approximately 1 inch thick at the injection site (abdomen preferred, at least 2 inches from navel).
• Insert the needle at 45–90° depending on body composition; release the pinch after needle insertion.
• Do not aspirate for subcutaneous injections; inject slowly and steadily.
• Withdraw the needle at the same angle; apply gentle pressure with clean gauze if needed.
• Rotate sites systematically to avoid lipohypertrophy or scarring.
• Dispose of used syringes immediately in a proper sharps container; never reuse needles.

Recommended Source

Note: Product availability and specifications subject to change. Verify current product details on supplier website.
Shop at Amino Labs